8-K: Monogram Amends Merger Agreement with Zimmer Biomet

Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. amended their merger agreement to revise the definition of 'Permitted Transfer' in the CVR Agreement following an SEC comment.

Summary

• Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. executed a First Amendment to their Agreement and Plan of Merger on August 27, 2025.
• The amendment was made in response to a verbal comment from the U.S. Securities and Exchange Commission (SEC).
• It specifically modifies the definition of 'Permitted Transfer' within the Form of CVR Agreement, which is Exhibit B to the original Merger Agreement, by deleting clause (g).
• The original Agreement and Plan of Merger was entered into on July 11, 2025.
• The merger involves Honey Badger Merger Sub, Inc., a wholly-owned subsidiary of Zimmer Biomet, merging into Monogram, with Monogram continuing as the surviving corporation and a wholly-owned subsidiary of Zimmer Biomet.

Sentiment

Score: 6

Explanation: The filing details a procedural amendment to an existing merger agreement, addressing a regulatory comment. This is a neutral to slightly positive development as it indicates progress in satisfying regulatory requirements without introducing new material issues.

Positives

• The amendment addresses a verbal comment from the SEC, indicating proactive compliance and progress towards satisfying regulatory requirements for the merger.
• The continued advancement of the merger process suggests the transaction remains on track.

Negatives

• No explicit negative impacts are detailed in the amendment; it is a technical adjustment.

Risks

• The existence of an SEC comment, even if addressed, highlights ongoing regulatory scrutiny inherent in complex merger transactions.
• The specific impact of deleting clause (g) from the 'Permitted Transfer' definition in the CVR Agreement is not fully detailed without the original clause, potentially introducing minor uncertainty regarding CVR terms.

Future Outlook

The amendment facilitates the ongoing merger process by addressing regulatory feedback, indicating continued progress towards the completion of the acquisition of Monogram Technologies Inc. by Zimmer Biomet Holdings, Inc.

Management Comments

• No notable direct quotes from management are provided in this filing; the document is a formal amendment signed by Benjamin Sexson (CEO of Monogram), Chad F. Phipps (SVP, General Counsel and Secretary of Zimmer Biomet), and Noel Knape (CFO of Monogram).

Industry Context

Mergers and acquisitions, particularly in the medical technology sector, frequently involve detailed regulatory reviews by bodies like the SEC. Amendments to merger agreements, especially concerning complex instruments like Contingent Value Rights (CVRs), are common procedural steps to ensure compliance and address regulatory feedback, reflecting the stringent oversight in such transactions.

Corporate Governance

Legal Proceedings

• No formal litigation or new regulatory proceedings are disclosed; the amendment addresses a verbal comment from the SEC regarding the merger agreement, which is a standard part of regulatory review.

Related Party Transactions

• No new related party transactions are disclosed beyond the existing merger agreement between Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc.

Stakeholder Impact

• Shareholders: Clarifies terms related to potential Contingent Value Rights (CVRs), which could impact future payouts if CVRs are part of the deal, and signals progress towards merger completion.
• Regulatory Bodies: Demonstrates compliance with SEC feedback, facilitating the regulatory approval process for the merger.

Next Steps

• Completion of the merger between Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc., subject to the remaining terms and conditions of the amended Merger Agreement.

Key Dates

Recommendation

The filing details a technical amendment to an existing merger agreement, addressing a regulatory comment. It does not introduce new financial data or strategic shifts that would warrant a change in investment recommendation, maintaining a 'hold' stance for investors awaiting merger completion.

Keywords

Monogram Technologies, Zimmer Biomet, Merger Agreement, SEC filing, MGRM, Acquisition, CVR Agreement, Permitted Transfer, Corporate Governance